PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Kidney Int. Author manuscript; available in PMC 2012 August 17.
Published in final edited form as:
PMCID: PMC3422025
NIHMSID: NIHMS300448

Renal CD14 expression correlates with the progression of cystic kidney disease

Abstract

Monocyte and macrophage markers are among the most highly overexpressed genes in cpk mouse kidneys with severely progressive renal cystic disease. We now demonstrate that one of these markers, CD14, is abnormally transcribed, activated and shed in cystic kidneys. However, these abnormalities are not associated with an increased number of interstitial CD14-positive mononuclear cells. Instead, we show that most non-cystic and cystic renal tubular epithelia are CD14-positive and that CD14 can be produced even by distal nephron-derived principal cells. Cd14 overexpression is significant in as early as 5-d old sporadically cystic cpk kidneys and it further increases during the disease progression. Similarly, in a cpk model with variable rates of cystic kidney disease progression, a (C57BL/6J-cpk × CAST/Ei)F1 intercross, Cd14 expression positively correlates with kidney volume in 10-d old mice, exceeding the correlation of a gene encoding an established autosomal dominant polycystic kidney disease (ADPKD) marker, MCP-1 (r=0.94 vs. r=0.79; both p<0.001). Similarly, in a small group of ADPKD patients (n=16), baseline urinary CD14 levels (but not GFR) correlate with a two-year rate of total kidney volume change (overall r=0.43, p=0.09; for males r=0.74, p=0.02) suggesting potential utility of CD14 in predicting ADPKD outcomes.

Keywords: polycystic kidney disease, cpk mouse, innate immune response, CD14, biomarkers

INTRODUCTION

Polycystic kidney disease (PKD) is a major cause of end-stage renal disease in children and adults.1 It affects over 600,000 people in the US and 12.5 million worldwide. Autosomal dominant PKD (ADPKD; MIM 173900; 173910) occurs in 1:400 to 1:1,000 individuals. ADPKD is caused by mutations in one of two genes, PKD1 or PKD2.25 Autosomal recessive PKD (RPKD; MIM 263200) occurs in 1:20,000 live births and is caused by defects in a single gene, PKHD1.6, 7

Innate immune system abnormalities are a dominant feature of both ADPKD and RPKD. In ADPKD, renal parenchyma is infiltrated by mononuclear cells,8 perhaps in response to accelerated production of monocyte chemotactic protein 1 (MCP-1).9, 10 We have observed monocytic infiltrates also in recessive PKD (RPKD).11 Until recently, these PKD-related innate immune response abnormalities were thought to be associated with advanced stages of the disease progression and were not considered to have a substantial impact on clinical outcomes. Discovery of abnormal urinary excretion of MCP-1 in early disease stages in ADPKD patients and an animal model 9, 10 changed this paradigm by demonstrating that innate immunity is altered early in the disease pathogenesis. In addition, several recent lines of evidence suggest that immune responses directly promote cystogenesis, at least in animal models.1215

To further elucidate the role of innate immune cells in PKD pathogenesis, we studied cpk mouse model of RPKD with variable rates of cystic kidney disease progression due to admixture of two genetic backgrounds.16 In this model we have identified sixty monocyte/macrophage-associated markers that are over-expressed in kidneys from cpk mice with severely vs. mildly progressive cystic kidney disease.11 An overexpression of macrophage markers associated with a wound healing- and fibrosis-promoting alternative activation pathway suggests that a PKD-associated mononuclear cell-like response contributes to the pathogenesis of interstitial fibrosis, a typical feature of advanced PKD. This hypothesis is consistent with the belief that interstitial inflammation is the leading cause of renal dysfunction in PKD.17, 18

The substantial magnitude of PKD-associated innate immune abnormalities was recently revealed by genome-wide transcription profiling studies. For example, in the cpk mouse model, genes encoding markers of macrophages, together with additional innate immune factors, represent the most highly over-expressed group of genes in a severely progressive cystic kidney disease.11 Similar abnormalities were revealed by genome-wide expression profiling study of Han:SPRD-Cy rat kidneys that were harvested months before measurable changes in renal function.19 The specific role of immunity in PKD pathogenesis is further suggested by cystogenesis-inhibiting effects of several immunosuppressive drugs (e.g., glucocorticoids, mycophenolate mofetil, and mTOR and TNFα inhibitors). 1215

In the current study, we characterize PKD-associated expression of CD14, a widely used marker of mature monocytes and macrophages and one of the most highly over-expressed genes in cpk mice with severely vs. mildly progressive cystic renal disease.11 CD14 is a pattern recognition receptor20 that operates in conjunction with Toll-like family of receptors (summarized in Kim et al.21) as a high affinity homing receptor for lipopolysacharide (LPS) playing a key role in LPS-induced immune response activation. However, it may also bind apoptotic cells and fungi. CD14 is highly expressed in mature monocytes and macrophages and to a lesser degree in a wide range of non-myeloid cell types including proximal tubular cells (summarized in Morrissey22). It is also found in milk, cerebrospinal fluid, serum and urine.

CD14 was originally described in mononuclear cells as a 55 kDa protein anchored to cell surface by linkage to glycosylphosphatidylinositol (GPI; mCD14).23 However, after activation of these cells (e.g., by LPS), soluble CD14 can be released in large quantities either by protease-dependent shedding (as approximately a 48 kDa fragment) or by protease-independent release of a larger (approximately 55 kDa) protein that escaped posttranslational modifications (including attachment of the GPI anchor)24 (see schema; Figure 1).

Figure 1
Schema of CD14-mediated immune response activation and CD14 shedding

In the current study, we present a comprehensive analysis of CD14 expression in kidneys of 10-d old cpk mice and its relationship to rates of renal cystic disease progression. We also characterize postnatal Cd14 gene expression in cpk and wild type mice. Finally, we examine CD14 protein content in mouse and human cystic kidneys and explore CD14’s potential as a putative marker for predicting rates of change in kidney volume in ADPKD.

RESULTS

Cd14 expression correlates with rates of renal cystic disease progression in cpk mice

We examined Cd14 gene expression profiles of cystic kidneys from 10-d old mice selected among an F2 cohort of affected cpk mice (n=461) that were generated in an (C57BL/6J-cpk/+ × CAST)F1 intercross.16 This intercross represents a model that provides variable rates of cystic kidney disease progression. Previously, we generated genome-wide renal expression analyses of the 7 most mildly affected and 7 most severely affected mice from this cross.11 In the current study, we examined renal Cd14 expression in the 7 most mildly affected mice, 8 mice selected evenly across phenotypic spectrum of renal cystic disease severity (defined by kidney length, weight and volume),16 and an additional 7 unaffected mice. Cd14 expression in these kidneys determined with quantitative TaqMan® assays correlated strongly with kidney volumes ((r=0.94, p<0.001); Figure 2a), resembling closely our initial Affymetrix 430 2.0 array-based Cd14 expression analyses (data not shown). However, there was a gender difference in these correlations (r=0.95 and p<0.001 for males, r=0.74 and p=0.02 for females).

Figure 2
Correlation between Cd14 expression and cystic kidney disease severity in cpk mice

Cd14 expression was more strongly correlated with kidney volume than expression of Ccl2, which showed moderately strong correlation with kidney volume (r=0.79, p<0.001; Figure 2b). Ccl2 encodes MCP-1, the only surrogate marker of PKD progression extensively validated in ADPKD patients and an animal PKD model.9, 10 Similar to the Cd14 expression data, these analyses closely resembled Affymetrix 430 2.0 array data generated during our initial evaluation of Ccl2 expression (data not shown).

Renal Cd14 expression in cpk mice is abnormally increased in early postnatal period

The above renal Cd14 gene expression data reflect a snapshot at 10-days of age across a spectrum of renal cystic phenotypes resulting from variable rates of disease progression. In the cpk model, these variable rates were induced by different admixtures of two distinct genetic backgrounds in the (C57BL/6J-cpk/+ × CAST)F1 intercross. To better characterize the temporal course of Cd14 expression during cystic disease progression, we examined its expression in 0-, 5-, 10-, 15-, 20- and 25-day old (P0-P25) kidneys from cpk and wild-type mice with an exclusive C57BL/6J genetic background. Consistent with previous observations of developmental regulation of CD14 expression in humans,25 these analyses revealed that renal Cd14 expression in wild type mice is developmentally regulated. Specifically, in the wild type kidneys Cd14 expression increased over 4-fold during the first 3 weeks of life (Figure 2c). In cpk kidneys, increase in Cd14 expression was even more accelerated, leading to a significant (1.4-fold; p<0.05) difference between cpk and wild-type kidneys by 5-days of age (Figure 2c). The Cd14 over-expression in cpk kidneys further increased with progressing age until P25, the last scored timepoint before presumable death due to uremia around 4 wks of age. In contrast, over-expression of Ccl2, an MCP-1 encoding gene, in cpk vs. wild type kidneys was less prominent and more variable (Figure 2d).

CD14+ mononuclear cell content is not significantly increased in cpk kidneys

Since monocytes and macrophages are major sources of CD14, we examined the numbers of these cells in 10-d old cpk kidneys. Staining with several anti-CD14 antibodies identified interstitial monocyte- and macrophage-like cells in both cystic cpk and wild-type kidneys. In contrast to Cd14 overexpression in cpk kidneys, the number of strongly CD14-positive interstitial cells per mm2 tissue (excluding cyst and tubular lumina) was not significantly increased in the cortex of cpk vs. wild-type kidneys, and it was significantly decreased in medulla of cpk vs. wild-type kidneys (Figure 3a–b). These data indicate that increased levels of Cd14 gene expression in cpk kidneys cannot be attributed to an increased number of interstitial CD14-positive mononuclear cells.

Figure 3
CD14-positive mononuclear cell content is not significantly increased in cpk kidneys

CD14 can be produced by cystic and non-cystic renal tubular epithelia

In addition to monocytes and macrophages, CD14 can be expressed by non-myeloid cells such as endothelial cells and proximal tubular cells (summarized in Morissey22). To determine whether these non-myeloid cells participate in CD14-associated innate immune responses in PKD, we compared patterns of antigenic CD14 expression/deposition in kidneys from 10-d old cpk mice vs. wild-type littermates. Similar to previous studies demonstrating that proximal tubular cells can produce CD14,22 our immunohistochemical analyses revealed varying intensities of CD14 protein staining that were detected in non-cystic tubular epithelia of wild-type and cpk kidneys (Figure 3a). In addition, cell membrane and cystoplasm of epithelial cell lining of most cpk cysts also stained with anti-CD14 antibody and the intensity of this staining was stronger in kidneys with more advanced disease (P15 and P20; Supplementary figure 1). This CD14 production by principal cells of collecting duct that form epithelial cell lining of most RPKD cysts has not been previously described. The capacity of these cyst-forming epithelial cells to produce CD14 protein is further supported by the presence of both Cd14 mRNA and CD14 protein in principal cells of a SV40-immortalized internal medullary collecting duct cell line mIMCD-K2 (Figure 3c).

cpk kidneys contain increased levels of shedded CD14 fragments

To explore whether the PKD-associated increase in Cd14 gene expression translates also to an increased generation and/or processing of the CD14 protein, we examined kidneys of 10-d old cpk and wild type mice by immunoblotting with anti-CD14 antibodies. In contrast to the gene expression profiling data, immunoblotting analyses showed decreased levels of total CD14 protein in cpk kidneys (Figure 4). However, the content of the 48 kDa CD14 variant that is generated by proteolytic shedding from immunologically activated or injured cells26 was significantly increased in the cpk vs. wild type kidneys (Figure 4).

Figure 4
CD14 producing cells are abnormally activated in cpk kidneys

CD14 processing is abnormal in human RPKD kidneys

Informed by CD14 expression and processing abnormalities in the cpk mouse, we also characterized CD14 expression in human PKD kidneys. First, we tested the expression of antigenic CD14 in kidneys from ~21-wk old control and RPKD fetuses. Similar to the 10-d old cpk kidneys, the RPKD kidneys contained strongly CD14-positive interstitial cells. However, cytoplasmic staining of human fetal cystic and non-cystic renal tubular cells was more intense when compared to CD14-positive interstitial cells (Figure 5a, left panel). Immunoblotting analyses of RPKD kidneys vs. control fetal kidneys (Figure 5b, left panel) closely parallel the lower CD14 content in cystic cpk vs. wild-type kidneys. Similarly, immunoprecipitated urine from RPKD patients with mild to moderately advanced disease (CrCl 39–123 ml/min) showed the presence of both soluble CD14 forms (48 and 55 kDa, Figure 5c).

Figure 5
CD14 expression in human RPKD and ADPKD

CD14 is abnormally processed and excreted in ADPKD

Consistent with previous reports of interstitial mononuclear cell infiltrates in ADPKD kidneys,8 we observed the presence of CD14+ mononuclear cells in interstitium of end-stage ADPKD kidneys (Figure 5a, right panel). In contrast to RPKD, CD14 staining of tubular epithelia in ADPKD was more sporadic and epithelial lining of only a subset of renal cysts was formed by CD14-positive cells.

Immunoblotting of human end-stage ADPKD kidneys resembled RPKD data with low CD14 content in cystic vs. normal control kidneys (Figure 5b, right panel). These data suggested that abnormal CD14 shedding in PKD kidneys is followed by its washout to urine or plasma. Consistent with this hypothesis, immunoprecipitated urine from ADPKD patients with mild to moderately advanced disease (CrCl 49–129 ml/min) showed the presence of both soluble CD14 forms (48 and 55 kDa, Figure 5c). The CD14 was present also in cyst fluid in approximately 10 to 100-fold higher concentrations than urinary CD14 levels (determined by ELISA).

CD14, a candidate predictor of ADPKD progression rates

Because Cd14 gene expression in cpk kidneys correlated strongly with rates of renal cystic disease progression (Figure 2), we speculated that urinary levels of shed CD14 may also correlate with rates of disease progression in ADPKD. Quantitative ELISA-based analyses of CD14 levels in a small group of ADPKD patients (n=16; 9 Caucasian males and 7 females; average iothalamate glomerular filtration rate (GFR) 86 ml/min) support this hypothesis. Specifically, baseline urinary CD14 levels correlated with a two-year rate of PKD progression determined by a relative change (second year follow up to baseline ratio) in total kidney volume (TKV; overall r=0.43, p=0.09; for males only r=0.74, p=0.02; Figure 6) suggesting potential utility of urinary CD14 levels for predicting ADPKD outcomes. Adjustment for urinary creatinine decreased these correlations (overall r=0.26, p>0.20, for males r=0.55, p=0.12). In comparison, the correlation of the relative TKV change with the initial iothalamate GFR was not significant (r=(−0.22), p>0.20) in the studied group of patients.

Figure 6
CD14 is a candidate predictor of ADPKD progression

In contrast to CD14, the correlation of urinary MCP1 levels with the rate of ADPKD progression was weak and did not reach statistical significance (overall r=0.19, for males only r=0.21, both p>0.20). Similarly, weaker correlations were obtained between Ccl2 (vs. Cd14) expression and rates of cystic kidney disease progression in cpk kidneys (Figure 2).

Since serum represents a potential source of urinary CD14 or, aternatively, renal CD14 may leak to systemic circulation, we also evaluated serum CD14 levels in this ADPKD cohort. The overall correlation of logarithmically adjusted serum CD14 values with a two-year rate of PKD progression determined by a relative TKV change (r=0.43, p=0.09, n=17) resembled correlations of urine CD14 values with TKV change. However, these correlations did not appear to vary by gender (r=0.44 males, r=0.42 females). Correlations between unadjusted as well as adjusted CD14 urinary and serum values were weak and not significant (r<0.25, p>0.20, n=28). Together, these data point to urine and serum CD14 as potentially independent candidate markers of PKD progression. However, these observations require validation on a larger well-characterized ADPKD cohort.

DISCUSSION

We have recently demonstrated that genes encoding CD14 and other innate immune system factors are most highly over-expressed in age-matched cpk mice with severe vs. mild rates of renal cystic disease progression.11 The current study confirmed and extended this initial observation.

Particularly intriguing is the finding of Cd14 over-expression in 5-d old cpk (vs. unaffected) kidneys (Figure 2c) that occurred in very early stages of the disease. Similarity between this early Cd14 expression pattern and that of Ccl2, a gene encoding the potent chemotactic factor MCP-1, which recruits mononuclear cells to sites of injury and inflammation (Figure 2d), suggests that the observed Cd14 expression abnormalities in cystic kidneys reflect accelerated mononuclear cell recruitment due to increased MCP-1 expression. However, we did not observe significantly higher numbers of CD14+ mononuclear cells in cystic cpk kidneys. Instead, our data suggest that alternative CD14-producing (e.g., epithelial) cells are the major source of early CD14 expression abnormalities in cystic kidneys. Since renal epithelial cells from proximal tubules22 and, as our data suggest, also from distal nephron segments, express CD14, it is likely that both CD14 and MCP-1 expression abnormalities in cpk kidneys reflect an independent response of renal tubular cells to the cystic disease-related injury and/or incomplete or aberrant tubular cell differentiation. The absence of early over-expression of genes encoding other macrophage markers (e.g., CD68 or CD163) in 5-d old cpk kidneys (data not shown) further supports this hypothesis. Interestingly, the Cd14 and Ccl2 expression abnormalities preceded significant changes in expression of Lcn2 (data not shown), a gene encoding an acute renal tubular injury marker NGAL (summarized by Devarajan27). Together, these observations suggest that innate immune abnormalities represent one of the earliest responses exerted by renal tubular cells affected by a cystogenesis-promoting gene defect. It is conceivable that these innate immune responses alter susceptibility of renal tubular cells to cystogenic stimuli. A reduction of cystogenesis by inhibition of TNFα,15 a downstream component of the CD14/TLR4 signaling pathway (summarized in Togbe et al. 28), is consistent with this hypothesis. This paradigm also suggests that immunosuppressive rather than antiproliferative effects of sirolimus and mycophenolate mofetyl are responsible for cystogenesis inhibiting effects of these drugs.13, 14

Triggers of CD14 over-expression in PKD remain to be determined. We speculate that in RPKD, where the cystically dilated renal tubules do not form cysts that are isolated from the nephron, CD14 may be a marker of renal tubular cells’ response to injury caused directly by the primary cystogenic defect. Alternatively, CD14 expression may reflect responses to renal epithelia injury caused by secondary or non-renal effects of cystogenic mutations (e.g., hypertension). Since several recent studies suggest that injury and/or renal tubular responses to injury are critical in cystogenesis (summarized in Verdeguer et al29 and Li et al 15), it is possible that CD14 levels may be associated with cystogenic potential or “nascent cyst formation”. We hypothesize that similar concepts can be applied to ADPKD, but with additional levels of complexity due to different responses in cells that sustained the “second cystogenic hit” (reviewed by Pei30) and haploinsufficient ADPKD cells that may form microcysts after an injury.31 Indeed, CD14 expression, processing and shedding may also reflect other effects of PKD on renal epithelia such as biomechanical effects of cyst expansion.

The specific consequences of increased renal CD14 expression, activation and shedding in PKD remain unknown. It is possible that intratubular CD14, as a potent stimulator of TNFα secretion,32 promotes cystogenesis primarily by activating the cystogenic TNFα pathway. However, CD14 effects are likely complex. Since the shed CD14 is a known mediator of renal endotoxin-induced tubulointerstitial injury,33 an endotoxin or other factors that bind to this pattern recognition receptor20 may also lead to immune activation and/or injury of renal tubular cells in a complex process that resembles the activation of professional immune cells. We speculate that this “immune activation” of renal epithelial cells changes their susceptibility to cystogenic stimuli across developmental stages and that this activation can be triggered by numerous factors that lead to substantial renal distress. For example, it is possible that CD14 activation accelerates cystogenesis before response to PKD defects is down-regulated at P12-14 (e.g., in an inducible orthologous Pkd1 model34). However, immune stimuli may promote cystogenesis also in mature kidneys with increased susceptibility to PKD defects. Such cystogenesis-promoting effects were observed e.g., after renal ischemia-reperfusion injury35 which, similarly to our PKD-related observations, leads to CD14 over-expression in renal tubular cells without increasing the number of infiltrating mononuclear cells.22

On a molecular level, as a major ligand for Toll-like receptor 4 (TLR4) CD14 may directly transactivate cystogenic pathways (reviewed in Torres and Harris36) modulated by TLR4 signaling, e.g., the Wnt pathway37 or Rho and PI3K pathways (reviewed by Ruse and Knaus38). Altered TLR4 signaling may also affect the AP-1 signaling pathway (reviewed in Hu et al. 39) that has been linked to cystogenesis in PKD1 defects.40 Since TLR4 is expressed across the nephron including proximal tubules and collecting ducts (summarized in Good et al 41), it is possible that renal tubular cell-derived CD14 may activate TLR4 locally in a paracrine (perhaps even autocrine) fashion. Alternatively, filtered or exosomal CD1442 (that may be in part proximal nephron-derived) may exert more distal effects, e.g., by activating TLR4 on principal cells of collecting duct, a major cyst-forming cell type.

Additional evidence supporting the role of CD14/TLR4 signaling in PKD pathogenesis stems from the fact that the Tlr4 gene is a candidate modifier of cystic kidney disease. It fulfills major modifier gene criteria established by the Complex Trait Consortium43: 1) it maps to 33 cM on chromosome 4 under the main quantitative trait locus for renal cystic and billiary phenotypes in cpk mice;16 2) its gene expression (data not shown) as well as the expression of its major ligand CD14 (Figure 2) correlates with the rates of cystic disease severity in cpk mice; 3) the Tlr4 gene has C57BL/6J and CAST/Ei strain-specific haplotypes with several functionally relevant variants; 4) it is predominantly expressed in the newborn period (according to EST Profile Viewer; http://www.ncbi.nlm.nih.gov/unigene) a time period most relevant to the studied modifier gene effect;16 5) it is expressed by both renal tubular and biliary epithelial cells;44, 45 and finally 6) TLR4 is a major regulator of cystogenic factor TNFα.15 However, Tlr4’s modifier gene effects have to be validated by functional studies.

In the current study we observed strong correlations between Cd14 expression and 10-d cpk kidney volumes that reflect rates of cystic disease progression in this model. To determine whether similar association between CD14 expression and the rate of disease progression exist also in ADPKD, we evaluated correlations between rates of cystogenesis (expressed as relative change in total kidney volume (TKV) over a two-year period) in a small group (n=16) of well-characterized patients selected from participants of the Emory ADPKD Cohort Study. Similar to studies that showed significant associations of unadjusted urine neutrophil gelatinase-associated lipocalin (NGAL) levels with high cyst growth rate in ADPKD46 and faster doubling of serum creatinine in other chronic kidney disorders47, our analyses presented in this manuscript revealed moderately strong correlations between unadjusted urinary CD14 levels and the rate of ADPKD (TKV) progression. However, our analyses are limited by small sample size that did not allow the evaluation of multiple covariate effects. Therefore, validation of these data has to be performed on a larger well-characterized cohort of ADPKD patients. Ideally, such analyses should also determine whether random or timed urinary CD14 excretion can be used as a short-term marker of disease activity that cannot be revealed by imaging studies due to too short follow up intervals. The use of CD14 as such a marker may allow a more accurate titration of supportive or future PKD specific therapies and may complement additional emerging markers of PKD progression, such as renal volume48 or specific small peptides detected by capillary electrophoresis coupled to mass spectrometry (CE-MS).49 CD14 may be especially useful as a marker if future therapies alter the CD14/TLR4 signaling pathway. In addition, it remains to be determined whether functional polymorphisms within CD14 gene (e.g., its promoter)50 influence specific PKD outcomes.

Finally, both Cd14 mRNA expression in the studied mouse kidneys and urinary CD14 levels in ADPKD patients correlated better with rate of kidney volume change in males than in females. We speculate that these gender differences reflect distinct female-specific innate immune responses that include regulation of CD14 levels.51 In addition, CD14 excretion in urine from females may be influenced by menstrual cycle similarly as excretion of other factors that activate components of CD14/TLR4 signaling (e.g., IL-152).

In summary, we have performed the first comprehensive analysis characterizing CD14 expression in PKD. In the cpk mouse, a model of recessive PKD, we determined that abnormalities in Cd14 gene expression represent an early postnatal event. In addition, in a model that provides variable rates of cystic kidney disease progression, Cd14 expression positively and strongly correlated with the rate of cystogenesis reflected by kidney volumes of 10-d old cpk kidneys. We showed that similar to renal ischemia-reperfusion injury, CD14 expression abnormalities in cpk kidneys cannot be attributed to increased numbers of CD14+ monocytes or macrophages, but rather they reflect increased immunological activity of renal tubular cells. Results of CD14 studies in human kidneys from patients with RPKD closely resembled observations in cpk kidneys, in particular with respect to CD14 immunolocalization and renal CD14 content. Interestingly, we observed CD14 expression abnormalities also in ADPKD kidneys and our initial analyses indicate that CD14 is a candidate predictor of ADPKD progression.

MATERIALS AND METHODS

Mice

Details of the generation of the (C57BL/6J-cpk/+ × CAST)F1 intercross and subsequent identification of cpk mutants among the F2 mice using Cys1cpk allele-specific assay were previously described.16, 53 All F2 mice were sacrificed 10 days after birth, their kidneys removed and their length, weight and volume recorded. One of the kidneys from each animal was snap-frozen and stored in liquid nitrogen, and the other was fixed in 10% buffered formalin for histological evaluation. Additional mice with C57BL/6J genetic background, either homozygous for the cpk mutation or their wild type (unaffected) littermates from the maintenance colony, were also sacrificed at postnatal days 0 to 25 and their kidneys harvested similarly to the above F2 mice. All protocols were approved by the University of Alabama at Birmingham (UAB) Institutional Animal Care and Use Committee. The University of Alabama at Birmingham is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International.

Gene expression profiling

We studied gene expression in mouse kidneys harvested from the (B6-cpk/+ × CAST)F1 intercross (7 with smallest kidney volume, 8 with kidney volumes evenly distributed across phenotypic spectrum of 461 cpk mice, and 7 unaffected controls). We also examined renal gene expression in cpk and wild type mice at postnatal day 0, 5, 10, 15, 20 and 25 (four biological replicas for each phenotype and timepoint). RNA and cDNA was prepared from whole kidneys as previously described.11 Initial gene expression analyses were performed on mice generated in the intercross using Affymetrix GeneChip® Mouse Genome 430 2.0 Arrays (Affymetrix Inc., Santa Clara, CA) according to a previously described protocol.11 All subsequent gene expression studies that are presented in this manuscript were performed with TaqMan® probes arranged into custom-designed low density arrays (Applied Biosystems, Foster City, CA). TaqMan® assays relevant to this manuscript include: Mm00438094_g1 (Cd14), Mm00441243_g1 (Ccl2) and Mm00607939_s1 (Actb; a gene encoding beta-actin). CT values were determined with 7000 SDS RQ software (version 1.1) and subsequently standardized using a CT value for Actb as reference. Actb was recommended as a suitable reference gene for this model based on equivalence testing (a two one-sided t-test)54 using the above Affymterix array data11 and TaqMan® Mouse Endogenous Control Array (Applied Biosystems). The standardized CT values were used to determine significance of studied associations.

Immunostaining and Immunoblotting

Formalin-fixed kidneys from affected cpk homozygous and unaffected wild type mice were paraffin embedded and cut into sections (3 and 5 μm). These were xylene-deparafinized, rehydrated, and stained using rabbit polyclonal anti-human CD14 (M-305) antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and species-specific secondary antibody conjugated with biotin (Molecular Probes, Eugene, OR). Immunostaining was performed after blocking tissue sections for 30 min with PBS containing 1% bovine serum albumin (Sigma, St Louis, MO). Primary antibody diluted in blocking buffer was allowed to react with the tissues for 12-hours at 4°C, followed by four rinses with PBS. Immunohistochemical detection was performed with ABC complex/HRP and DAB chromogen (DAKO) after blocking with Avidin/Biotin blocking kit (Vector Laboratories, Burligame, CA). Stained tissue sections were analyzed with bright field microscopy using a Nikon E600 microscope equipped with a SPOT Insight digital camera (Diagnostic Instruments, Sterling Heights, MI). Renal CD14-positive cell counts were quantified by histomorphometry with Image Pro Plus v5.1 image analysis software (Media Cybernetics, Inc., Bethesda, MD). For each section and stain, six images each of cortex and medulla from different locations were selected systematically to minimize selection bias. For each image, CD14-positive cells were enumerated and the tissue area, excluding cyst and tubular lumina, were measured. Each CD14-positive cell was visually confirmed to assure exclusion of nonspecifically stained debris. Results were expressed as stained cells/mm2 tissue. Statistical evaluations were performed with SPSS 11.5 statistical software package (SPSS Inc.).

For immunoblotting, whole kidneys from three 10-d old cpk homozygotes with C57BL/6J genetic background, and kidneys from three age-matched wild type B6 mice were homogenized in lysis buffer containing 150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 1% Nonidet P40, 0.5% sodium deoxycholate, 0.7% Pepstatin and 1 tablet Complete Protein inhibitor per 50 ml (Roche Diagnostics, Penzberg, Germany). After 10-min centrifugation at 10,000 × g, the supernatant containing solubilized membranes as well as cytosolic material was denatured for 5 min at 95°C in 2X Laemmli reducing buffer, and was separated by 4–12% gradient SDS-PAGE (Invitrogen, Carlsbad, CA). The gel was electrophoretically transferred onto a Hybond-ECL membrane (Amersham, Piscataway, NJ) using a wet blotter (Invitrogen). The membrane was blocked with 5% nonfat milk in 1X PBS/0.05% Tween-20 for one hour at room temperature. Subsequent washing and dilutions were done with 1X PBS/0.05% Tween-20 at room temperature. The CD14 (M-305) antibody and anti-beta-actin antibody (Sigma) were detected after incubation with species-specific secondary antibodies conjugated with HRP (Molecular Probes). Activated chemiluminescence was captured on Hyperfilm-ECL (Amersham).

The expression of CD14 protein in mIMCD-K2 cell line of SV40 transformed internal medullary collecting duct cells (gift from Erik Schwiebert, University of Alabama at Birmingham) was validated with reverse-transcriptase PCR (RT-PCR) using intron-spanning primers that generate 258 bp and 375 bp products from cDNA and genomic DNA, respectively (5′-gcctttctcggagcctatct-3″ and 5′-tggcttcggatctgagaagt-3′).

Remnant human fetal RPKD and non-PKD kidneys were collected after obtaining informed consent according to a protocol approved by the Institutional Review Board of University of Alabama at Birmingham (UAB). This Board also approved the protocol for collection and analyses of remnant adult nephrectomized end-stage ADPKD kidneys, control kidneys and urine that were used in this study. The tissue processing, immunostaining and immunoblotting were performed in similar fashion as described above for mouse tissues.

CD14 quantification in human serum and urine

Serum and urine from patients enrolled in the Emory ADPKD Cohort Study were collected and analyzed according to protocols approved by Institutional Review Boards at Emory University and University of Alabama at Birmingham. CD14 levels were determined using a CD14 ELISA assay (R&D Systems, Minneapolis, MN), according to manufacturer’s protocol. Absorbances of technical duplicates were determined using Spectra Microplate Reader (Molecular Devices, Sunnyvale, CA). Statistical analyses were performed with SPSS 11.5 statistical software package (SPSS Inc.).

Supplementary Material

Suppl Figure 1

Supplementary figure 1: CD14 staining in cpk mice with advanced cystic kidney disease:

Micrographs of anti-CD14 antibody stained sections show moderately strong staining of cystic epithelia in cpk kidneys with advanced cystic disease progression (postnatal day 15 and 20; P15 and P20; staining of age-matched wild wild-type littermates (+/+) is shown for comparison).

Acknowledgments

This work was supported in part by the Polycystic Kidney Disease Foundation Grant-In-Aid (M.M.), Pilot and Feasibility study from UAB Recessive PKD Core Center P30 DK074038 (M.M), American Heart Association National Scientist Development Grant (MM), UAB Digestive Disease Research Development Center DK064400 (LES) and AI083539 (LES). Dr. Cui was supported in part by the UAB-UCSD O’Brien Center 1P30 DK079337. Histology services were provided by the UAB Animal Resources Program Comparative Pathology Laboratory. A portion of this work was presented at the American Society of Nephrology Annual Meeting 2008 and published in abstract form.

Footnotes

DISCLOSURE

The authors declared no competing interests.

References

1. Gabow P. Autosomal dominant polycystic kidney disease. N Eng J Med. 1993;329:332–342. [PubMed]
2. The European Polycystic Kidney Disease Consortium. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. Cell. 1994;77:881–894. [PubMed]
3. The American PKD1 Consortium. Analysis of the genomic sequence for the autosomal dominant polycystic kidney disease (PKD1) gene predicts the presence of a leucine-rich repeat. Hum Mol Genet. 1995;4:575–582. [PubMed]
4. The International Polycystic Kidney Disease Consortium. Polycystic kidney disease: the complete structure of the PKD1 gene and its protein. Cell. 1995;8:289–298. [PubMed]
5. Mochizuki T, Wu G, Hayashi T, et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science. 1996;272:1339–1342. [PubMed]
6. Onuchic L, Furu L, Nagasawa Y, et al. PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple IPT domains and PbH1 repeats. Am J Hum Genet. 2002;70:1305–1317. [PubMed]
7. Ward C, Hogan M, Rossetti S, et al. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet. 2002;30:259–269. [PubMed]
8. Zeier M, Fehrenbach P, Geberth S, Mohring K, Waldherr R, Ritz E. Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int. 1992 Nov;42(5):1259–1265. [PubMed]
9. Cowley BD, Jr, Ricardo SD, Nagao S, Diamond JR. Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats. Kidney Int. 2001 Dec;60(6):2087–2096. [PubMed]
10. Zheng D, Wolfe M, Cowley BD, Jr, Wallace DP, Yamaguchi T, Grantham JJ. Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2003 Oct;14(10):2588–2595. [PubMed]
11. Mrug M, Zhou J, Woo Y, et al. Overexpression of innate immune response genes in a model of recessive polycystic kidney disease. Kidney Int. 2008 Jan;73(1):63–76. [PubMed]
12. Gattone VBD, Cowley J, Barash B, Nagao S, Takahashi H, Grantham J. Methylprednisolone retards the progression of inherited polycystic kidney disease in rodents. Am J Kidney Dis. 1995;25:302–313. [PubMed]
13. Mei C, Wang L, Xiong X, et al. Experimental research on the treatment of autosomal dominant polycystic kidney disease with mycophenolate mofetil. J Am Soc Nehrol. 2007;18:364A.
14. Shillingford JM, Murcia NS, Larson CH, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5466–5471. [PubMed]
15. Li X, Magenheimer BS, Xia S, et al. A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease. Nat Med. 2008 Aug;14(8):863–868. [PMC free article] [PubMed]
16. Mrug M, Li R, Cui X, Schoeb TR, Churchill GA, Guay-Woodford LM. Kinesin family member 12 is a candidate polycystic kidney disease modifier in the cpk mouse. J Am Soc Nephrol. 2005 Feb 23;16:905–916. [PubMed]
17. Grantham J. Mechanisms of progression in autosomal dominant polycystic kidney disease. Kidney Int. 1997;63:S93–S97. [PubMed]
18. Torres VE. New insights into polycystic kidney disease and its treatment. Curr Opin Nephrol Hypertens. 1998 Mar;7(2):159–169. [PubMed]
19. Burtey S, Riera M, Fontes M. Overexpression of complement components genes in Han:SPRD rats a model of polycystic kidney disease. Kidney Int. 2008;73(11):1324–1325. author reply 1325. [PubMed]
20. Pugin J, Heumann ID, Tomasz A, et al. CD14 is a pattern recognition receptor. Immunity. 1994 Sep;1(6):509–516. [PubMed]
21. Kim JI, Lee CJ, Jin MS, et al. Crystal structure of CD14 and its implications for lipopolysaccharide signaling. J Biol Chem. 2005 Mar 25;280(12):11347–11351. [PubMed]
22. Morrissey J, Guo G, McCracken R, Tolley T, Klahr S. Induction of CD14 in tubular epithelial cells during kidney disease. J Am Soc Nephrol. 2000 Sep;11(9):1681–1690. [PubMed]
23. Haziot A, Chen S, Ferrero E, Low MG, Silber R, Goyert SM. The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J Immunol. 1988 Jul 15;141(2):547–552. [PubMed]
24. Bufler P, Stiegler G, Schuchmann M, et al. Soluble lipopolysaccharide receptor (CD14) is released via two different mechanisms from human monocytes and CD14 transfectants. Eur J Immunol. 1995 Feb;25(2):604–610. [PubMed]
25. Jones CA, Holloway JA, Popplewell EJ, et al. Reduced soluble CD14 levels in amniotic fluid and breast milk are associated with the subsequent development of atopy, eczema, or both. J Allergy Clin Immunol. 2002 May;109(5):858–866. [PubMed]
26. Bazil V, Strominger JL. Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. J Immunol. 1991 Sep 1;147(5):1567–1574. [PubMed]
27. Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease. Scand J Clin Lab Invest Suppl. 2008;241:89–94. [PMC free article] [PubMed]
28. Togbe D, Schnyder-Candrian S, Schnyder B, et al. Toll-like receptor and tumour necrosis factor dependent endotoxin-induced acute lung injury. Int J Exp Pathol. 2007 Dec;88(6):387–391. [PubMed]
29. Verdeguer F, Le Corre S, Fischer E, et al. A mitotic transcriptional switch in polycystic kidney disease. Nat Med. 2010 Jan;16(1):106–110. [PMC free article] [PubMed]
30. Pei Y. A “two-hit” model of cystogenesis in autosomal dominant polycystic kidney disease? Trends Mol Med. 2001 Apr;7(4):151–156. [PubMed]
31. Bastos AP, Piontek K, Silva AM, et al. Pkd1 haploinsufficiency increases renal damage and induces microcyst formation following ischemia/reperfusion. J Am Soc Nephrol. 2009 Nov;20(11):2389–2402. [PubMed]
32. Sundan A, Gullstein-Jahr T, Otterlei M, et al. Soluble CD14 from urine copurifies with a potent inducer of cytokines. Eur J Immunol. 1994 Aug;24(8):1779–1784. [PubMed]
33. Bussolati B, David S, Cambi V, Tobias PS, Camussi G. Urinary soluble CD14 mediates human proximal tubular epithelial cell injury induced by LPS. Int J Mol Med. 2002 Oct;10(4):441–449. [PubMed]
34. Piontek K, Menezes LF, Garcia-Gonzalez MA, Huso DL, Germino GG. A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. Nat Med. 2007 Dec;13(12):1490–1495. [PMC free article] [PubMed]
35. Patel V, Li L, Cobo-Stark P, et al. Acute kidney injury and aberrant planar cell polarity induce cyst formation in mice lacking renal cilia. Hum Mol Genet. 2008 Jun 1;17(11):1578–1590. [PMC free article] [PubMed]
36. Torres VE, Harris PC. Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol. 2006 Jan;2(1):40–55. quiz 55. [PubMed]
37. Malhotra S, Kincade PW. Canonical Wnt pathway signaling suppresses VCAM-1 expression by marrow stromal and hematopoietic cells. Exp Hematol. 2009 Jan;37(1):19–30. [PMC free article] [PubMed]
38. Ruse M, Knaus UG. New players in TLR-mediated innate immunity: PI3K and small Rho GTPases. Immunol Res. 2006;34(1):33–48. [PubMed]
39. Hu X, Chen J, Wang L, Ivashkiv LB. Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation. J Leukoc Biol. 2007 Aug;82(2):237–243. [PubMed]
40. Le NH, van der Wal A, van der Bent P, et al. Increased activity of activator protein-1 transcription factor components ATF2, c-Jun, and c-Fos in human and mouse autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2005 Sep;16(9):2724–2731. [PubMed]
41. Good DW, George T, Watts BA., 3rd Lipopolysaccharide directly alters renal tubule transport through distinct TLR4-dependent pathways in basolateral and apical membranes. Am J Physiol Renal Physiol. 2009 Oct;297(4):F866–874. [PubMed]
42. Gonzales PA, Pisitkun T, Hoffert JD, et al. Large-scale proteomics and phosphoproteomics of urinary exosomes. J Am Soc Nephrol. 2009 Feb;20(2):363–379. [PubMed]
43. Abiola O, Angel JM, Avner P, et al. The nature and identification of quantitative trait loci: a community’s view. Nat Rev Genet. 2003 Nov;4(11):911–916. [PMC free article] [PubMed]
44. Karrar A, Broome U, Sodergren T, et al. Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology. 2007 Apr;132(4):1504–1514. [PubMed]
45. Wolfs TG, Buurman WA, van Schadewijk A, et al. In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-gamma and TNF-alpha mediated up-regulation during inflammation. J Immunol. 2002 Feb 1;168(3):1286–1293. [PubMed]
46. Bolignano D, Coppolino G, Campo S, et al. Neutrophil gelatinase-associated lipocalin in patients with autosomal-dominant polycystic kidney disease. Am J Nephrol. 2007;27(4):373–378. [PubMed]
47. Bolignano D, Lacquaniti A, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol. 2009 Feb;4(2):337–344. [PubMed]
48. Kistler AD, Poster D, Krauer F, et al. Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int. 2009 Jan;75(2):235–241. [PubMed]
49. Kistler AD, Mischak H, Poster D, Dakna M, Wuthrich RP, Serra AL. Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2009 Jul;76(1):89–96. [PubMed]
50. Yamazaki K, Ueki-Maruyama K, Oda T, et al. Single-nucleotide polymorphism in the CD14 promoter and periodontal disease expression in a Japanese population. J Dent Res. 2003 Aug;82(8):612–616. [PubMed]
51. Lodrup Carlsen KC, Lovik M, Granum B, Mowinckel P, Carlsen KH. Soluble CD14 at 2 yr of age: gender-related effects of tobacco smoke exposure, recurrent infections and atopic diseases. Pediatr Allergy Immunol. 2006 Jun;17(4):304–312. [PubMed]
52. Lynch EA, Dinarello CA, Cannon JG. Gender differences in IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist secretion from mononuclear cells and urinary excretion. J Immunol. 1994 Jul 1;153(1):300–306. [PubMed]
53. Hou X, Mrug M, Yoder B, et al. Cystin, a novel cilia-associated protein, is disrupted in the cpk mouse model of polycystic kidney disease. J Clin Invest. 2002;109:533–540. [PMC free article] [PubMed]
54. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987 Dec;15(6):657–680. [PubMed]